VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.
Also called NCT06873321
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Science Valley Research Institute
- Registry
-
NCT06873321
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Brazil
- Registry status
- Recruiting
Technical summary
Registry record NCT06873321. Randomized; single masking; primary purpose prevention. Start 2024-02-24 (actual); primary completion 2025-07-20 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization
- Acronym
- RESOLUTION
- Condition
- Peripheral Arterial Disease
- Condition
- Venous Thormboembolism
- Condition
- Cardiovascular Diseases
- Condition
- Vascular Surgery Patient with PAD / Carotid Stenosis
- Intervention (Drug)
- rivaroxaban 2.5 mg bid + aspirin 100 mg
- Intervention (Drug)
- clopidogrel 75 mg od for 3 months followed by aspirin 100 mg od for endovascular procedures or aspirin for open procedures
- Lead sponsor
- Science Valley Research Institute
Record details
- Record id
cardio:ct-nct06873321- Content hash
616175b659a728c38accf7c651d6c0c9cb02376b097f1b87fb2131113aa42e0f